US Solicitor Sides With Sandoz In Biosimilar Case

Law360, New York (December 20, 2016, 12:50 PM EST) -- Elizabeth Flanagan

Gina Nellesen The U.S. Solicitor General recently recommended that the U.S. Supreme Court grant certiorari and review the questions presented in both the petition and conditional cross-petition in Sandoz v. Amgen, No. 15-1039, and Amgen v. Sandoz, 15-1195. Each petition concerns provisions of the biosimilar statute, the Biologics Price Competition and Innovation Act, set forth at 42 U.S.C. § 262(l). Representing the interests of the United States government as amicus curiae to the court, the solicitor urges review because proper interpretation of the BPCIA will have a "significant impact" on the operation of the patent dance and on the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!